Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B
Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.
Summary
Phase 1 Study of BW-20507 in Healthy Subjects and Patients With Chronic Hepatitis B. Ia involved a single ascending dose study where healthy participants were administered one dose of BW-20507 or placebo subcutaneously. Ib involved a multiple ascending dose study where participants with chronic hepatitis B virus infection were administered with multiple doses of BW-20507 SC
Official title: A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Chinese Healthy Subjects and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity in Chinese Subjects With Chronic HBV Infection
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2024-06-24
Completion Date
2025-12-29
Last Updated
2026-06-26
Healthy Volunteers
Yes
Conditions
Interventions
Placebo
Solution for injection
BW-20507
Solution for injection
Locations (4)
Argo Investigative Site
Beijing, Beijing Municipality, China
Argo Investigative Site
Chongqing, Chongqing Municipality, China
Argo Investigative Site
Guanzhou, Guangdong, China
Argo Investigative Site
Xuzhou, Jiangsu, China